Overall verdict
Neutral
5.3/10
1-year performance
+14.45%
Score breakdown
Up 14.5% over 1 year, 70% of the 52-week range.
Strongest: Valuation 7.7/10. Weakest: Growth 0.9/10.
28 analysts, target +0.0% vs the price.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand ; migraine products under the Nurtec ODT/Vydura and Zavzpret brand ;
vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands ; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity ; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands ;
and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Founded
1849
Employees
75 000
Revenue / employee
834 387 USD
Next earnings
February 2, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.41%
- Bank of New York Mellon Corp0.80%
- FMR LLC0.32%
- Rest of the register96.48%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
31.44 USD
52-week low
23.62 USD
1-year performance
14.45%
Rising
Year-to-date performance
16.35%
Rising
Drawdown
-7.55%
Mild pullback
Position in the 52-week range
70% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 1.4 times harder.
$10,000 placed at the end of December 2000 are worth today
| Pfizer | $18,939 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.4 times as much as the world ETF.
- Worst fall:-65 % between December 2000 and February 2009. $10,000 placed at the top fell to $3,478. The world ETF, at worst: -53 %. Back to its high in 56 months.
Pfizer earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Pfizer: $18,939
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 25.00 USD - 27.14 USD (3 methods agree)
The price implies growth of 0.37% per year; the company grows at -3.57%.
Gross margin 65.1%, net margin 6.3%, ROIC 2.7%, ROE 4.4%.
Net margin
6.34%
Low
Sector 9.99%|S&P 13.40%
Gross margin
65.10%
High
Return on equity (ROE)
4.44%
Low
Sector 6.74%|S&P 17.06%
Return on invested capital (ROIC)
2.70%
Low
Free cash flow margin (FCF)
18.53%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.92x
Exceptional
Margin stability
11.6 pts
Very uneven
Revenue to net income
Growth
0.9/10Revenue down 0.4% over 1 year, 8.5% a year over 5, EPS -3.6% a year over 5.
Revenue (trailing 12 months)
63.6Md USD
Revenue growth (1y)
-0.43%
Declining
Revenue growth (3y)
-37.63%
Declining
EPS growth (1y)
-9.04%
Declining
EPS CAGR (5y)
-3.57%
Declining
EPS revisions (3 months)
2.51%
Revised up
Valuation
7.7/10P/E 41.6x, forward P/E 18.1x, EV/EBITDA 7.3x. The multiple sits in the 79th percentile of its own 5-year history.
P/E (TTM)
41.6x
Expensive
Sector 27.7x|S&P 23.6x
Forward P/E
18.1x
Fair
EV / EBITDA
7.3x
Cheap
Sector 14.3x|S&P 15.5x
PEG
—
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
26.07 USD
Overvalued
P/E vs its own 5-year history
among the 21% highest valuations
Pricier than usual
Market cap
166Md USD
Financial strength
6.2/10Cash covers 22.8% of the debt, net debt/EBITDA 2.3x.
Net debt / EBITDA
2.3x
Tight
Gearing (net debt / equity)
54.20%
Solid
Cash
14.3Md USD
Cash / market cap
8.61%
Solid
Cash / total debt
22.77%
Tight
Interest coverage
6.1x
Solid
Net debt
48.4Md USD
Equity
89.3Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 29.36 USD
- MM2029.85
- MM5028.79
- MM20026.94
- RSI 1449.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.73%
200-day average slope, 3 months
+4.04%
50-day average slope, 1 month
+3.97%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.62 % per day
Volatility change
+32.61%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.61 (7) | 3.05 (23) | 63 127 (25) | 24 369 (11) | 8 565 (8) |
| 2027 | 2.15 (8) | 2.95 (24) | 60 821 (25) | 24 562 (13) | 11 690 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.3 | 4.6 | 166Md USD | 41.6x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.1 % | 14.5 % |
